Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius SE & Co. KGaA    FRE   DE0005785604

FRESENIUS SE & CO. KGAA

(FRE)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius : Kabi Introduces Neostigmine Methylsulfate Injection, USP Simplist Prefilled Syringe in 3 mg per 3 mL Presentation

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/11/2019 | 10:06am EDT

LAKE ZURICH - Fresenius Kabi announced today the immediate availability in the United States of Neostigmine Methylsulfate Injection, USP in 3 mg per 3 mL Simplist ready-to-administer prefilled syringes.

Fresenius Kabi is a global health company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition.

The Fresenius Kabi Simplist Neostigmine Injection prefilled syringe is the first manufacturer-prepared, ready-to-administer prefilled syringe on the market. Fresenius Kabi has sold Neostigmine Injection, USP in 0.5 mg per 1 mL and 1 mg per 1 mL vial presentations since 2015.

'Fresenius Kabi is pleased to continue the expansion of our convenient Simplist prefilled syringe portfolio,' said John Ducker, president and CEO of Fresenius Kabi USA. 'This is the fourth Simplist product we've introduced this year and represents the strength of our pipeline of important therapies and delivery systems that can help physicians practice more efficiently.'

About Simplist Neostigmine Methylsulfate Injection, USP

Neostigmine Methylsulfate Injection, a cholinesterase inhibitor, is indicated for intravenous use for reversal of the effects of nondepolarizing neuromuscular blocking agents (NMBA) after surgery.

Important Safety Information

An anticholinergic agent, e.g., atropine sulfate or glycopyrrolate, should be administered prior to or concomitantly with neostigmine methylsulfate.

Neostigmine is contraindicated in patients with: Hypersensitivity to neostigmine.

Peritonitis or mechanical obstruction of the urinary or intestinal tracts.

Neostigmine has been associated with bradycardia: Atropine or glycopyrrolate should be administered prior to administration of neostigmine methylsulfate injection to lessen risk of bradycardia.

Coexisting Conditions: Patients with known cardiac disease, cardiac arrhythmias, or recent coronary artery occlusion may be particularly sensitive to the hemodynamic effects of neostigmine; their blood pressure and electrocardiogram should be continuously monitored with the initiation of neostigmine treatment and for a duration sufficient to assure hemodynamic stability.

Neuromuscular Dysfunction: Can occur if large doses of neostigmine methylsulfate are administered when there is minimal neuromuscular blockade; reduce the dose if recovery from neuromuscular blockade is nearly complete.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176, option 5, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

This Important Safety Information does not include all the information needed to use Neostigmine Methylsulfate Injection, USP safely and effectively.

About Fresenius Kabi

Fresenius Kabi (www.fresenius-kabi.com/us) is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company's products and services are used to help care for critically and chronically ill patients. The company's U.S. headquarters is in Lake Zurich, Illinois. The company's global headquarters is in Bad Homburg, Germany.

Contact:

Lake Zurich

Tel: (847) 550-2300

Email: communications.USA@fresenius-kabi.com

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FRESENIUS SE & CO. KGAA
07/18CVS to Test a Device For Dialysis at Home -- WSJ
DJ
07/09Drugmakers Rise After Trump Pricing Rule Is Blocked
DJ
07/02FRESENIUS SE & CO. KGAA : Notification and public disclosure of transactions by ..
EQ
07/01FRESENIUS SE & CO. KGAA : Release according to Article 40, Section 1 of the WpHG..
EQ
06/30FRESENIUS SE & CO. KGAA : Release according to Article 41 of the WpHG [the Germa..
EQ
06/27FRESENIUS SE & CO. KGAA : Release according to Article 40, Section 1 of the WpHG..
EQ
06/21FRESENIUS SE & CO. KGAA : Release according to Article 40, Section 1 of the WpHG..
EQ
06/14FRESENIUS : Medical Care successfully places USD bonds
PU
06/12FRESENIUS SE & CO. KGAA : Release according to Article 40, Section 1 of the WpHG..
EQ
06/11FRESENIUS : Kabi Introduces Neostigmine Methylsulfate Injection, USP Simplist Pr..
AQ
More news
Financials (EUR)
Sales 2019 35 372 M
EBIT 2019 4 641 M
Net income 2019 1 883 M
Debt 2019 19 742 M
Yield 2019 1,78%
P/E ratio 2019 13,4x
P/E ratio 2020 12,5x
EV / Sales2019 1,27x
EV / Sales2020 1,17x
Capitalization 25 200 M
Chart FRESENIUS SE & CO. KGAA
Duration : Period :
Fresenius SE & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS SE & CO. KGAA
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 56,64  €
Last Close Price 45,26  €
Spread / Highest target 56,8%
Spread / Average Target 25,2%
Spread / Lowest Target -28,3%
EPS Revisions
Managers
NameTitle
Stephan Sturm President & Chief Executive Officer
Gerd Krick Chairman-Supervisory Board
Rachel Clare Empey Chief Financial Officer
Niko Stumpfögger Deputy Chairman-Supervisory Board
Klaus-Peter Müller Member-Supervisory Board
Sector and Competitors